Sulfacetamide Sodium NDC 24470-935

NDC codes

FDA NDC Directory

Product NDC (as listed)24470-935Labeler and product segments. Claims need a package NDC.

Product NDC at billing width24470-0935Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
24470-935-12	24470093512	355 mL in 1 BOTTLE, PLASTIC (24470-935-12)Marketed from Jan 23, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sulfacetamide Sodium
Generic name (nonproprietary): sulfacetamide sodium
Active ingredients: Sulfacetamide sodium — 100 mg/mL
Dosage form: Gel
Route: Topical
Labeler: Cintex Services, LLC
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Jan 23, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Sulfonamides (Chemical structure)
Identifiers: Product ID 24470-935_0fa3302e-b2b5-6b9b-e063-6394a90abc2cSPL ID 0fa3302e-b2b5-6b9b-e063-6394a90abc2cSPL set ID 0fa3302e-b2b4-6b9b-e063-6394a90abc2cRxCUI 1006107UNII 4NRT660KJQ
Pharmacologic class: Sulfonamide Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N424470093512 followed by a unit qualifier and the quantity

Package 24470-0935-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 23, 2024.

Indications (excerpt from the label)

INDICATIONS: This product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)